Frequencies of CBFB-MYH11 fusion types among 208 patients with inv(16)/t(16;16) AML in our study and 162 patients reported by Schnittger et al18
| Fusion type . | This study (n = 208)* . | Schnittger et al18 (n = 162)† . | P‡ . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| Type A | 182 | 87 | 128 | 79 | .03 |
| Type E | 18 | 9 | 8 | 5 | .22 |
| Type D | 6 | 3 | 16 | 10 | .007 |
| Other types | 2§ | 1 | 10‖ | 6 | .006 |
| Fusion type . | This study (n = 208)* . | Schnittger et al18 (n = 162)† . | P‡ . | ||
|---|---|---|---|---|---|
| No. . | % . | No. . | % . | ||
| Type A | 182 | 87 | 128 | 79 | .03 |
| Type E | 18 | 9 | 8 | 5 | .22 |
| Type D | 6 | 3 | 16 | 10 | .007 |
| Other types | 2§ | 1 | 10‖ | 6 | .006 |
AML indicates acute myeloid leukemia.
All patients were diagnosed with de novo AML.
One hundred thirty-eight patients were diagnosed with de novo AML and 24 patients with treatment-related AML. Within the de novo AML cohort, 83% had type A fusions; frequencies for other fusion types within this cohort were not provided.
P values are from the Fisher exact test.
Both fusions were type I (n = 2).
These were the following fusion types: Avar (n = 1), Bvar (n = 1), F (n = 1), G (n = 2), H (n = 1), J (n = 2), and S/L (n = 2).